Polycystic ovary syndrome (PCOS) and idiopathic hirsutism (IH) are androgen excess disorders requiring the determination of classic androgen levels for diagnosis. 11-oxygenated androgens have high androgenic potential, yet their clinical value in those disorders is not clear. Additionally, the role of endocrine disruptors (EDs), particularly in IH, remains understudied. We analyzed 25 steroids and 18 EDs in plasma samples from women with IH, PCOS, and controls using LC-MS/MS. Cytokine levels and metabolic parameters were assessed. Comparisons included non-obese women with PCOS (n = 10), women with IH (n = 12) and controls (n = 20), and non-obese versus obese women with PCOS (n = 9). Higher levels of 11-oxygenated androgens were observed in women with PCOS compared to those with IH, but not controls. Conversely, 11-oxygenated androgen levels were lower in women with IH compared to controls. Cytokine levels did not differ between women with IH and controls. Bisphenol A (BPA) levels were higher in obese women with PCOS compared to non-obese women with PCOS. Bisphenol S occurrence was higher in women with PCOS (90%) compared to controls (65%) and IH (50%). Significant correlations were found between androgens (11-ketotestosterone, androstenedione, testosterone) and insulin and HOMA-IR, as well as between immunomodulatory 7-oxygenated metabolites of DHEA and nine interleukins. Our data confirms that PCOS is a multiendocrine gland disorder. Higher BPA levels in obese women might exacerbate metabolic abnormalities. IH was not confirmed as an inflammatory state, and no differences in BPA levels suggest BPA does not play a role in IH pathogenesis.
Background: Circulating steroid trajectories after robot‐assisted radical prostatectomy are poorly characterized from the day‐of‐surgery baseline, and relevant biology extends beyond testosterone and dihydrotestosterone to adrenal‐derived 11‐oxygenated androgens and steroid conjugate turnover. This study aimed to characterize 3‐ and 6‐month plasma steroid differences from a day‐of‐surgery baseline and evaluate baseline steroid biomarkers for adverse pathology, upgrading, and early detectable prostate‐specific antigen (PSA). Methods: This prospective, single‐center cohort included 173 men undergoing robot‐assisted radical prostatectomy. Fasting plasma was sampled before premedication on the morning of surgery and at 3 and 6 months. A 34‐analyte steroid panel, including conjugated analytes, was quantified using liquid chromatography–tandem mass spectrometry. Longitudinal differences were analyzed using mixed‐effects models. Baseline screening used logistic regression with false discovery rate correction and adjusted models for retained signals. Results: For most analytes, 168–170 baseline samples and 131/108 samples at 3/6 months were available. Relative to baseline, 11‐ketotestosterone increased at 3 and 6 months (fold changes 1.36 [95% CI 1.24–1.49] and 1.25 [1.13–1.38]), corticosterone decreased (0.61 [0.52–0.70] and 0.59 [0.51–0.69]), cortisol decreased (0.91 [0.84–1.00] and 0.86 [0.78–0.94]), and conjugated corticosterone/corticosterone increased (1.96 [1.57–2.45] and 2.41 [1.90–3.06]), all p < 0.04. At 6 months, neither testosterone (fold change 0.88; 95% CI 0.75–1.03) nor dihydrotestosterone (0.90; 0.79–1.04) differed significantly from the day‐of‐surgery baseline. The conjugated/unconjugated estrone ratio (E1C/E1) was the only retained baseline adverse‐pathology signal, with inverse adjusted associations for pT3a/b disease (OR 0.61; 95% CI 0.41–0.90; p = 0.013) and composite adverse pathology (OR 0.53; 95% CI 0.36–0.78; p = 0.001). No biomarker remained significant for upgrading or detectable PSA. Conclusions: Relative to the day‐of‐surgery baseline, longitudinal differences involve corticosteroid‐related and 11‐oxygenated analytes, but their mechanisms remain unresolved. These data define postoperative steroid trajectories from a day‐of‐surgery baseline without establishing prostatectomy‐specific endocrine effects. Baseline E1C/E1 warrants external validation as a hypothesis‐generating marker of adverse pathology.